Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...
A groundbreaking study shows findings that show a treatment can shrink tumors and improve survival outcomes for patients with ...
Bernstam, MD, discusses updated findings from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan-dlnk in heavily ...
MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal ...
The London Company Income Equity portfolio returned 12.3% year-to-date vs. a 14.4% increase in the Russell 1000 Value Index.
Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...
Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback